Participants will be placed on either drug or placebo and get routine normal care for 6 months. At the start and end of the study, participants will undergo different clinical measurements to see if the drug makes the sleep apnea better. ...
相信该试验的研究结果将在现有证据的基础上,能进一步证实 SGLT-2 抑制剂在降低 2 型糖尿病患者心血管风险方面的有益作用。 References: [1].List J, E.A. Abstract 2339. in AHA. 2014. [2].Sonesson, C., et al., Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and differe...
T2DM患者的SGLT2表达显著增加1.Vallon V,et al. Am J Physiol Renal Physiol. 2013 Jan 15;304(2):F156-67.2. DeFronzo RA,et al. Diabetes Obes Metab. 2012 Jan;14(1):5-14. 动物研究:SGLT2受抑制时,SGLT1反馈性增加肾脏对葡萄糖的重吸收急性SGLT2抑制剂(10mg/kg ip)急性SGLT2抑制剂(10mg/kg ...
These are the primary mechanisms of action of the SGLT2-inhibitor class that have been purported to be responsible for its beneficial effects, however as our understanding of this drug class evolves there is a recognition that there may be other novel pathways at play – we explore these pathwa...
SGLT2抑制剂的研发历程：从基础到临床 SGLT2抑制剂的研发历程：从基础到临床 目录 1SGLT2：肾脏最重要的葡萄糖转运体2家族性肾性糖尿症的启示3SGLT2抑制剂的研发与药代动力学研究 肾脏的生理:尿液的形成 血液肾小球 重吸收Na+、Cl+、K+和水等物质分泌K+、H+、NH3 近曲小管 远曲小管 集合管 原尿 髓袢 尿...
drug class also leads to concerns about AEs associated with its osmotic diuresis effects leading to volume depletion and orthostatic hypotension; however, these remained less than 3% across all treatment arms and were mild to moderate in nature.37–39 Meanwhile, SGLT2 inhibitors have a non-...
This finding suggested that the drug effects of EMPA on the renal and circulating protein profiles were mutually independent. Furthermore, correlation analysis showed no significant correlation between circulating and renal tissue pro- teins in the db/db and EMPA groups (Fig. 3C). Pathway ...
(1.1–7.9 μM)30, while IV infusion of the drug is well tolerated up to concentrations of 38 μM22. For that, our in-vitro work focused on canagliflozin concentrations of 5–30 μM. Radiotherapy response was investigated in a variety of doses (2–8 Gy) but focused mostly on 2...
also reported that SGLT2 inhibitors were the most effective drug to prevent CKD progression since the discovery of RAS inhibitors [62]. Causland et al. concluded that dapagliflozin did not significantly reduce the frequency of kidney composite outcomes [64]. Effect of SGLT2 inhibitors in IgA ...
In the first case, the effects of sotagliflozin on PPG should be evident a few hours after drug ingestion, independently of its plasma half-life. Daily drug administration, however, has shown positive effects on both fasting plasma glucose (FPG) and PPG. In a dose-ranging study, the ...